STAT3 and brain cancer: In mammary and brain cancer cells [MMF + ruxolitinib] significantly inhibited the phosphorylation of STAT3 and STAT5 after 12h of treatment by > 50%, as would be expected based on the declared kinase specificity of ruxolitinib (Figure 3A, p < 0.05).